Figures
Abstract
Objective
To investigate the associations of Insulin-like growth factor-II (IGF2) gene, Insulin-like growth factor-II receptor (IGF2R) gene and Insulin-like growth factor-II binding protein 2 (IGF2BP2) gene polymorphisms with the susceptibility to gestational diabetes mellitus (GDM) in Chinese population.
Methods
A total of 1703 pregnant women (835 GDM and 868 Non-GDM) were recruited in this case-control study. All participants underwent prenatal 75 g oral glucose tolerance test (OGTT) examinations during 24–28 gestational weeks at the Maternal and Child Health Hospital of Hubei Province from January 15, 2018 to March 31, 2019. Genotyping of candidate SNPs (IGF2 rs680, IGF2R rs416572, IGF2BP2 rs4402960, rs1470579, rs1374910, rs11705701, rs6777038, rs16860234, rs7651090) was performed on Sequenom MassARRAY platform. Logistic regression analysis was conducted to investigate the associations between candidate SNPs and risk of GDM. In addition, multifactor dimensionality reduction (MDR) method was applied to explore the effects of gene-gene interactions on GDM risk.
Results
There were significant distribution differences between GDM group and non-GDM group in age, pre-pregnancy BMI, education level and family history of diabetes (P < 0.05). After adjusted for age, pre-pregnancy BMI, education level and family history of diabetes, there were no significant associations of the candidate SNPs polymorphisms and GDM risk (P > 0.05). Furthermore, there were no gene-gene interactions on the GDM risk among the candidate SNPs (P > 0.05). However, the fasting blood glucose (FBG) levels of rs6777038 CT carriers were significantly lower than TT carriers (4.69±0.69 vs. 5.03±1.57 mmol/L, P < 0.01), and the OGTT-2h levels of rs6777038 CC and CT genotype carriers were significantly lower than TT genotype carriers (8.10±1.91 and 8.08±1.87 vs. 8.99±2.90 mmol/L, P < 0.01).
Citation: Li W, She L, Zhang M, Yang M, Zheng W, He H, et al. (2024) The associations of IGF2, IGF2R and IGF2BP2 gene polymorphisms with gestational diabetes mellitus: A case-control study. PLoS ONE 19(5): e0298063. https://doi.org/10.1371/journal.pone.0298063
Editor: Ramu Adela, National Institute of Pharmaceutical Education and Research Guwahati, INDIA
Received: September 1, 2023; Accepted: January 18, 2024; Published: May 3, 2024
Copyright: © 2024 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The data that support the findings of this study is openly available in figshare at: https://doi.org/10.6084/m9.figshare.25286227.v1.
Funding: This work was supported by the Health Commission of Hubei Province (WJ2018H0134, WJ2018H0145). The funders had role in data collection and analysis, decision to publish and preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
1. Introduction
Gestational diabetes mellitus (GDM) is characterized by glucose intolerance with onset or first recognized during pregnancy, which is a common complication of pregnancy [1]. The incidence of GDM is gradually increasing worldwide, and the pooled incidence in China is as high as 14.8% [2]. The adverse outcomes associated with GDM in pregnant women and their offspring are diverse, such as preeclampsia, neonatal hypoglycemia, macrosomia, type 2 diabetes mellitus (T2DM) and so on [1,3,4]. Therefore, it is crucial to identify potential risk factors of GDM for the health of women and children.
As a status of pre-diabetic, GDM is generally considered to be similar to T2DM in pathogenic mechanism, which is related to β-cell dysfunction and insulin resistance (IR) [5–9]. Insulin-like growth factor-II (IGF2) is a peptide with a similar structure to insulin that promotes β-cell proliferation and survival, and it has been shown to be involved in the identification of insulin that regulates growth and metabolism [10,11]. Insulin-like growth factor-II receptor (IGF2R), also known as mannose-6-phosphate receptor (M6P), is the scavenger receptor of IGF2 and it is important for limiting the bioavailability of IGF2 and regulating its glucose regulatory activity [12]. The insulin-like growth factor-II binding protein 2 (IGF2BP2/IMP2) is one of the mRNA binding protein family translated by IGF2 and is highly expressed in islets [13].
Previous studies have shown that IGF2 [14], IGF2R [15], IGF2BP2 [16,17] gene polymorphisms are related to T2DM, but limited researches have been conducted in GDM. And so far, only the role of IGF2BP2 polymorphism in GDM has been involved in genome-wide association studies (GWAS) in different populations [18,19]. Wu et al. conducted a meta-analysis in 2016 which showed that IGF2BP2 rs4402960 was significantly associated with increased GDM risk [20], but negative conclusions were drew in Tarnowski’s study subsequently [21]. The associations of IGF2, IGF2R and IGF2BP2 gene polymorphisms with GDM risk are still ambiguous in Chinese population. Therefore, the purpose of the case-control study was to explore the associations between IGF2, IGF2R, IGF2BP2 polymorphisms and the risk of GDM in Wuhan, China.
2. Materials and methods
2.1 Study population
Pregnant women who underwent prenatal examination at the Obstetrics and Gynecology Clinic of Maternal and Child Health Hospital of Hubei Province from January 15, 2018 to March 31, 2019 were consecutively enrolled in our study. After fasting for 8–12 hours, all subjects were given a routine 75 g oral glucose tolerance test (OGTT) at 24 to 28 gestational weeks. GDM was diagnosed when one or more following plasma values equaled or exceeded: fasting blood glucose (FBG) ≥ 5.1 mmol/L (92 mg/dl), 1-hour blood glucose (OGTT-1h) ≥ 10.0 mmol/L (180 mg/dl), and 2-hour blood glucose (OGTT-2h) ≥ 8.5 mmol/L (153 mg/dl) [22]. The non-diabetic pregnant women matched with gestational weeks were randomly selected as the non-GDM group. Exclusion criteria were: age < 18 years, ethnic minorities, pre-gestational diabetes, multiple pregnancies, pregnancies complicated with endocrine diseases such as hypertension and polycystic ovary syndrome, any other medical condition that might affect glucose regulation, unable or unwilling to participate in the study, and samples failure genotyped. Finally, 1703 pregnant women (835 GDM and 868 Non-GDM) were recruited in this case-control study. All subjects were unrelated and lived in Wuhan, Hubei Province, central China.
The method of data collection was reported in a previous article [23]. According to the Chinese standard for obesity, pregnant women could be diagnosed as underweight (< 18.5 kg/m2), normal (18.5 kg/m2 ≤ BMI < 24 kg/m2), overweight (24 kg/m2 ≤ BMI < 28 kg/m2) and obese (≥ 28 kg/m2). This study involving participants was reviewed and approved by the institutional review board of Wuhan University of Science and Technology, and was based on the principles of the Declaration of Helsinki. All participants provided their written informed consent for participation.
2.2 Selection and genotyping of SNPs
According to the results of T2DM GWAS, minor allele frequency (MAF) > 0.05 reported in the Chinese population, and tracking the latest results of IGF2/IGF2R/IGFBP2 polymorphisms with GDM risk [20,24,25], we finally selected 9 SNPs (rs680, rs416572, rs4402960, rs1470579, rs1374910, rs11705701, rs6777038, rs16860234, rs7651090) that might be associated with the risk of GDM. Plasma glucose measurements were performed by glucose oxidase method on the Cobas 8000 Modular Analyzer Series (Roche, Mannheim). At recruitment, 2mL fasting peripheral venous blood was collected and placed in EDTA anticoagulant tube. After separation, it was packed in 1.5mL EP tube and stored at -80 °C until analysis. Genomic DNA was isolated from 0.5mL blood cells using approved guideline of the Relax Gene Blood DNA System DP348 (Tiangen, China). According to the manufacturer’s instructions, the Sequenom MassARRAY platform (Sequenom, San Diego, California, USA) was used to genotype candidate SNPs, and a preliminary experiment was performed before formal genotyping. For quality control, 5% of duplicate samples were selected in a blind analysis. The call rates of rs680, rs416572, rs4402960, rs1470579, rs1374910, rs11705701, rs6777038, rs16860234, rs7651090 were 99.35%, 99.35%, 99.00%, 98.47%, 99.12%, 98.65%, 98.06%, 98.59% and 98.83% respectively, which were higher than the quality control standard (95%). In addition, the statistical power in this study was higher than 0.90.
2.3 Statistical analyses
The Kolmogorov-Smirnov test was used to test the normality of the distribution of continuous variables. Normal distribution data was expressed as mean ± standard deviation (SD), and differences among groups were compared by unpaired Student’s t-test. Chi-square test was used for qualitative data. The Hardy-Weinberg Equilibrium test (HWE) was applied to test whether the participants were representative of the population. Chi-square test of goodness of fit was used to measure the coincidence between the observed number of genotypes and the HWE of all genotype frequencies at the locus. If P was above 0.05, the sample of this genotype conformed to the law of genetic equilibrium, which suggested that the sample had good population representation. SNPS that did not meet the HWE test were not included in subsequent analyses. The Box-Tidwell method was used to check the assumptions for the logistic regression as age was a continuous variable, and the result showed there was a linear relationship between age and logit (P) (P = 0.18 > 0.05). Logistic regression was performed to evaluate the associations of genotypes and GDM risk. SHesis online software was used to analyze the linkage disequilibrium (LD) among IGFBP2 gene SNPs and construct haplotypes (http://analysis.bio-x.cn/myAnalysis.php). The Multifactor dimension reduction (MDR) method was applied to evaluate gene-gene interactions on GDM risk. One-way ANOVA analysis was used to investigate the relationships between SNPs and blood glucose levels, and post hoc analyses were performed by the Least Significant Difference (LSD) method. G-Power 3.1 software was used for power analysis for the study. All the statistical analyses were conducted by SPSS Software, Version 26.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was accepted as statistically significant.
3. Results
3.1 Demographic and clinical characteristics
The demographic and clinical characteristics of the participants were shown in Table 1. Compared with non-GDM group, women with GDM had a higher FBG, OGTT-1h, OGTT-2h, age, pre-gestational BMI and education level (P < 0.01). In addition, the proportion of GDM patients with a family history of diabetes was higher than non-GDM patients (29.96% vs. 12.06%, P < 0.01).
3.2 Associations between candidate SNPs polymorphisms and GDM
The distributions of rs680, rs416572, rs4402960, rs1470579, rs11705701, rs6777038, rs16860234 and rs7651090 in the non-GDM group were all in HWE (P > 0.05), except for rs1374910 (P < 0.05). The genotype distributions of the remaining 8 candidate SNPs in the GDM and non-GDM groups and their associations with GDM were presented in Table 2. After adjusted for age, pre-gestational BMI, education level and family history of diabetes, there were no significant associations of the candidate SNPs polymorphisms and GDM risk (P > 0.05).
3.3 LD analysis and haplotype construction among SNPs of IGFBP2 gene
The LD analysis among candidate SNPs of IGF2BP2 gene was shown in Fig 1. The results showed that there was a strong LD among rs4402960, rs1470579 and rs7651090 (D’>0.900, r2>0.850). Then haplotype construction was carried out, and the results showed that there were three haplotypes: GAA, TAG and TCG (Table 3). But no significant correlation was found between them and the risk of GDM.
3.4 Gene-gene interactions to GDM
Gene-gene interactions analysis indicated that both two-factor model (rs680, rs416572) and three-factor model (rs680, rs416572 and rs16860234) had good cross-validation consistency at 7/10, and the test accuracy of the two-factor model (0.50) was higher than the three-factor model (0.49), so the best model was the two-factor model. After further analysis, there was no significance of the test set in the two-factor gene-gene interactions (P > 0.05), as shown in Table 4.
3.5 Relationships between candidate SNPs polymorphisms and glycemic levels
Table 5 presented that the FBG levels of rs6777038 CT carriers were significantly lower than TT genotypes carriers (4.69±0.69 vs. 5.03±1.57 mmol/L, P < 0.01), and the OGTT-2h levels of rs6777038 CC and CT genotype carriers were significantly lower than TT genotype carriers (8.10±1.91 and 8.08±1.87 vs. 8.99±2.90 mmol/L, P < 0.01).
4. Discussion
In this case-control study, we analyzed the associations of eight candidate SNPs polymorphisms (IGF2 rs680, IGF2R rs416572, IGF2BP2 rs4402960, rs1470579, rs11705701, rs6777038, rs16860234, rs7651090) with GDM risk, except for rs1374910, which was excluded due to not meet with the HWE test. The results showed that candidate SNPs polymorphisms were not associated with increased GDM risk in Wuhan, China. Moreover, there were no gene-gene interactions on the GDM risk among the candidate SNPs.
IGF2 gene located in chromosome 11p15.5 region, the same as insulin [26]. IGF2 can promote pancreatic β-cell growth and re-expression during cell replication, renewal and apoptosis [11]. Although IGF2 is an important insulin signaling molecule, there are few studies on the correlations between rs680 polymorphism and T2DM [24,27,28]. Khan et al. showed that rs680 was associated with T2DM risk [27,28], but had no significant correlations with GDM in India [11], which was consistent with our results in Chinese population.
As the scavenger of IGF2, IGF2R has been shown to play a key role in glucose metabolism [29,30]. IGF2R is located on chromosome 6q26, a region that contains a genetic marker associated with insulin resistance traits in Mexican—Americans [30]. A previous study has shown that rs416572 in IGF2R 3’UTR region may be associated with the risk of T2DM [15,30]. But our results showed that rs416572 was not associated with GDM risk in Wuhan, China.
IGF2BP2 is located on chromosome 3q27 and binds to the 5’-UTR regions of IGF2 mRNA [31]. IGF2BP2 regulates pancreatic β cell function by inhibiting the first stage of insulin secretion. Previous studies have shown that IGF2BP2 rs4402960 [32], rs1470579 [33,34] and rs11705701 [33] were correlated with T2DM. But Xie et al. reported a negative result between rs1470579 and GDM risk in Chinese population [35], and Tarnowski et al. showed that rs11705701 was also not correlated with the risk of GDM in Poland [21], both of which were consistent with our research results. The associations between rs4402960 polymorphism and the risk of GDM remains controversial [20,21,36–38]. Previous studies have shown that rs4402960 is a susceptibility gene locus for GDM in Japan [36] and Korea [37], but this conclusion has not been obtained in Russia population [38]. Our results also showed that rs4402960 was not associated with the risk of GDM in Chinese population, which was consistent with the conclusion of recent meta-analysis [38,39].
To our knowledge, limited studies have been conducted to explore the correlations of rs6777038, rs16860234 and rs7651090 polymorphisms with GDM [40]. Only Salem showed that these three loci were associated with glutamic acid decarboxylase antibodies (GADA) negative diabetes [40]. The results of this study showed that these three candidate loci were not associated with the risk of GDM. In addition, the results of this study also showed that there were significant differences in FBG and OGTT-2h levels of rs6777038 genotypes, indicating that blood glucose only had a partial effect on the occurrence of GDM.
As disease susceptibility can’t be attributed to a single polymorphism or allele, but rather to a combination of multiple polymorphisms [41–44]. We evaluated gene-gene interactions using multifactor dimension reduction (MDR), a novel method to examine the combined effects of multiple factors in disease susceptibility [45]. The results showed that there were no gene-gene interactions on the GDM risk among the candidate SNPs, which needs to be further verified.
Our study has the following strengths. First, we selected 8 SNPs to explore their correlations with GDM, and as far as we know this is the first study to detect the relationships between IGF2R rs416572, IGF2BP2 rs7651090, rs6777038, rs16860234 and GDM. Second, we used MDR method to explore the gene-gene interactions on the GDM risk among the candidate SNPs. Finally, the sample size of this study is relatively large and the statistical power for each SNP is higher than 0.90, so the results are reliable.
However, there are some limitations in this study. First, the subjects were all from hospitals, which may exist admission rate bias, and further population-based studies will be needed. Second, we did not eliminate the effects of all confounding factors, such as dietary habits and exercise patterns. Third, since our results were all negative, clinicians still could not identify high-risk individuals by these sites. Finally, the levels and activities of IGF2, IGF2R and IGF2BP2 were not detected in this study. Therefore, more studies will be needed in the future to verify the results of this study.
5. Conclusions
In conclusion, the study revealed that IGF2 rs680, IGF2R rs416572, IGF2BP2 rs4402960, rs1470579, rs11705701, rs6777038, rs16860234, rs7651090 polymorphisms were not significantly associated with GDM in Wuhan, China. Further lager multicenter researches are needed to confirm these results.
References
- 1. Wendland E M, Torloni M R, Falavigna M, et al. Gestational diabetes and pregnancy outcomes-a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childb, 2012, 12(1): 1–13. pmid:22462760
- 2. Gao C, Sun X, Lu L, et al. Prevalence of gestational diabetes mellitus in mainland China: a systematic review and meta-analysis. J Diabetes Invest, 2019, 10(1): 154–162.
- 3. Hammoud N M, Visser G H A, van Rossem L, et al. Long-term BMI and growth profiles in offspring of women with gestational diabetes. Diabetologia, 2018, 61(5): 1037–1045. pmid:29492638
- 4. Vounzoulaki E, Khunti K, Abner SC, et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ, 2020,75 (10), 589–591. pmid:32404325
- 5. Dalfra M G, Burlina S, Del Vescovo G G, et al. Genetics and epigenetics: new insight on gestational diabetes mellitus. Front Endocrinol. 2020, 11: 602477. pmid:33335512
- 6. Kavian Z, Sargazi S, Majidpour M, et al. Association of SLC11A1 polymorphisms with anthropometric and biochemical parameters describing Type 2 Diabetes Mellitus. Scientific reports. 2023, 13(1): 6195.
- 7. Sargazi S, Mollashahi B, Sargazi S, et al. Prevalence of miR146a Gene Polymorphisms in Diabetic and Non-diabetic Patients with Chronic Kidney Disease. Iran J Sci Technol Trans Sci. 2022, 46: 21–31.
- 8. Sadeghi M B, Nakhaee A, Saravani R, et al. Significant association of LXRβ (NR1H2) polymorphisms (rs28514894, rs2303044) with type 2 diabetes mellitus and laboratory characteristics. Journal of diabetes and metabolic disorders. 2021, 20(1): 261–270.
- 9. Sadeghi M B, Nakhaee A, Saravani R, et al. SIRT1 functional polymorphisms (rs12778366, rs3758391) as genetic biomarkers of susceptibility to type 2 diabetes mellitus in Iranians: a case-control study and computational analysis. Int J Diabetes Dev Ctries. 2021, 41: 447–455.
- 10. Livingstone C, Borai A. Insulin-like growth factor-II: its role in metabolic and endocrine disease. Clin Endocrinol, 2014;80 (6):773–781. pmid:24593700
- 11. Khan IA, Jahan P, Hasan Q, et al. Genetic confirmation of T2DM meta-analysis variants studied in gestational diabetes mellitus in an Indian population. Diabetes Metab Synd, 2019, 13(1): 688–694.
- 12. Jeyaratnaganthan N, Hojlund K, Kroustrup PJ, et al. Circulating levels of insulin-like growth factor-II/mannose-6-phosphate receptor in obesity and type 2 diabetes. Growth Horm IGF Res, 2010, 20(3): 185–191. pmid:20110184
- 13. Dai N, Rapley J, Angel M, et al. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev, 2011, 25(11): 1159–1172. pmid:21576258
- 14. Mercader J M, Liao R G, Bell A D, et al. A loss-of-function splice acceptor variant in IGF2 is protective for type 2 diabetes. Diabetes, 2017, 66(11): 2903–2914. pmid:28838971
- 15. Chanprasertyothin S, Jongjaroenprasert W, Ongphiphadhanakul B. The association of soluble IGF2R and IGF2R gene polymorphism with type 2 diabetes. J Diabetes Res, 2015, 216383. pmid:25922844
- 16. Zeggini E, Weedon NM, Lindgren C M, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science, 2007, 316(5829): 1336–1341. pmid:17463249
- 17. Saxena R, Voight B F, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science, 2007, 316(5829): 1331–1336. pmid:17463246
- 18. Grarup N, Rose C S, Andersson E A, et al. Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes, 2007, 56(12): 3105–3111. pmid:17827400
- 19. Chauhan G, Spurgeon C J, Tabassum R, et al. Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians. Diabetes, 2010, 59(8): 2068–2074. pmid:20424228
- 20. Wu L, Cui L, Tam HW, et al. Genetic variants associated with gestational diabetes mellitus: a meta-analysis and subgroup analysis. Sci Rep-UK, 2016, 6(1): 1–9. pmid:27468700
- 21. Tarnowski M, Bujak J, Kopytko P, et al. Effect of FTO and IGF2BP2 gene polymorphisms on duration of pregnancy and Apgar scores in women with gestational diabetes. J Obstet Gynaecol, 2019, 39(2): 151–156. pmid:30371117
- 22. Metzger B E, Gabbe S G, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010 33(3), 676–682 pmid:20190296
- 23. She L, Li W, Guo Y, et al. Association of glucokinase gene and glucokinase regulatory protein gene polymorphisms with gestational diabetes mellitus: A case-control study. Gene, 2022, 824: 146378. pmid:35276241
- 24. Petry C J, Seear R V, Wingate D L, et al. Associations between paternally transmitted fetal IGF2 variants and maternal circulating glucose concentrations in pregnancy. Diabetes, 2011, 60(11): 3090–3096. pmid:21926269
- 25. Zhang C, Bao W, Rong Y, et al. Genetic variants and the risk of gestational diabetes mellitus: a systematic review. Hum Reprod Update, 2013, 19(4): 376–390. pmid:23690305
- 26. Casellas A, Mallol C, Salavert A, et al. Insulin-like growth factor 2 overexpression induces β-cell dysfunction and increases beta-cell susceptibility to damage. J Biol Chem, 2015, 290(27): 16772–16785.
- 27. Khan I A, Poornima S, Jahan P, et al. Type 2 diabetes mellitus and the association of candidate genes in Asian Indian population from Hyderabad, India. J Clin Diagn Res: J Clin Diagn Res, 2015, 9(11): GC01. pmid:26673680
- 28. Khan I A, Vattam K, Jahan P, et al. Importance of glucokinase-258G/A polymorphism in Asian Indians with post-transplant and type 2 diabetes mellitus. Intractable & rare Dis Res, 2016, 5(1): 25–30. pmid:26989645
- 29. Minchenko D O, Tsymbal D O, Davydov V, et al. Expression of genes encoding IGF1, IGF2, and IGFBPs in blood of obese adolescents with insulin resistance. Endocr Regul, 2019, 53(1): 34–45. pmid:31517621
- 30. Villuendas G, Botella-Carretero J I, Lopez-Bermejo A, et al. The ACAA-insertion/deletion polymorphism at the 3’UTR of the IGF-II receptor gene is associated with type 2 diabetes and surrogate markers of insulin resistance. Eur J Endocrinol, 2006, 155(2): 331–336. pmid:16868148
- 31. Christiansen J, Kolte A M, Nielsen F C. IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes. J Mol Endocrinol, 2009, 43(5): 187–195. pmid:19429674
- 32. Rao P, Wang H, Fang H, et al. Association between IGF2BP2 polymorphisms and type 2 diabetes mellitus: a case-control study and meta-analysis. Int J Env Res Pub He, 2016, 13(6): 574. pmid:27294943
- 33. Sargazi S, Nia HM, Saravani R, et al. IGF2BP2 polymorphisms as genetic biomarkers for either schizophrenia or type 2 diabetes mellitus: a case-control study. Gene Rep, 2020, 20: 100680.
- 34. Abuhendi N, Qush A, Naji F, et al. Genetic polymorphisms associated with type 2 diabetes in the Arab world: a systematic review and meta-analysis. Diabetes Res Clin Pr, 2019, 151: 198–208. pmid:30954515
- 35. Xie K, Chen T, Zhang Y, et al. Association of rs10830962 polymorphism with gestational diabetes mellitus risk in a Chinese population. Sci Rep-UK, 2019, 9(1): 1–6. pmid:30926842
- 36. Benny P, Ahn H J, Burlingame J, et al. Genetic risk factors associated with gestational diabetes in a multi-ethnic population. PloS one, 2021, 16(12): e0261137. pmid:34928995
- 37. Cho Y M, Kim T H, Lim S, et al. Type 2 diabetes-associated genetic variants discovered in the recent genome-wide association studies are related to gestational diabetes mellitus in the Korean population. Diabetologia, 2009, 52(2): 253–261. pmid:19002430
- 38. Popova P V, Klyushina A, Vasilyeva L B, et al. Association of common genetic risk variants with gestational diabetes mellitus and their role in GDM prediction. Front Endocrinol, 2021, 12: 628582. pmid:33953693
- 39. Liu J, Song G, Zhao G, et al. Lack of association between IGF2BP2 rs4402960 polymorphism and gestational diabetes mellitus: a case-control study, meta-analysis and trial sequential analysis. Bioscience Rep, 2020, 40(7). pmid:32662505
- 40. Salem S D, Saif-Ali R, Ismail I S, et al. IGF2BP2 alternative variants associated with glutamic acid decarboxylase antibodies negative diabetes in Malaysian subjects. PLoS One, 2012, 7 (9), e45573. pmid:23029108
- 41. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000, 26(2):163–175. pmid:11017071
- 42. Galavi H, Noorzehi N, Saravani R, et al. Genetic polymorphism in ADRB-1 is associated with type 2 diabetes susceptibility in Iranian population. Gene Reports. 2018, 12: 171–174.
- 43. Sargazi S, Nia M H, Sargazi F M, et al. SNPs in the 3’-untranslated region of SLC30A8 confer risk of type 2 diabetes mellitus in a south-east Iranian population: Evidences from case-control and bioinformatics studies. Journal of diabetes and metabolic disorders. 2020, 19(2): 979–988. pmid:33553018
- 44. Sargazi S, Ravanbakhsh M, Nia M H, et al. Association of Polymorphisms within HOX Transcript Antisense RNA (HOTAIR) with Type 2 Diabetes Mellitus and Laboratory Characteristics: A Preliminary Case-Control Study. Dis Markers. 2022, 2022: 4327342. pmid:35359879
- 45. Gui W, Liang J, Lin X, et al. Association of Genetic Variants in IGF2-Related Genes with Risk of Metabolic Syndrome in the Chinese Han Population. Front Endocrinol. 2021, 12, 654747. pmid:34093434